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ABSTRACT
The sudden emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and, more recently, Middle East-
ern respiratory syndrome CoV (MERS-CoV) underscores the importance of understanding critical aspects of CoV infection and
pathogenesis. Despite significant insights into CoV cross-species transmission, replication, and virus-host interactions, success-
ful therapeutic options for CoVs do not yet exist. Recent identification of SARS-CoVNSP16 as a viral 2=-O-methyltransferase
(2=-O-MTase) led to the possibility of utilizing this pathway to both attenuate SARS-CoV infection and develop novel therapeu-
tic treatment options. Mutations were introduced into SARS-CoVNSP16 within the conserved KDKEmotif and effectively at-
tenuated the resulting SARS-CoVmutant viruses both in vitro and in vivo. While viruses lacking 2=-O-MTase activity had en-
hanced sensitivity to type I interferon (IFN), they were not completely restored in their absence in vivo. However, the absence of
either MDA5 or IFIT1, IFN-responsive genes that recognize unmethylated 2=-O RNA, resulted in restored replication and viru-
lence of the dNSP16mutant virus. Finally, using the mutant as a live-attenuated vaccine showed significant promise for possible
therapeutic development against SARS-CoV. Together, the data underscore the necessity of 2=-O-MTase activity for SARS-CoV
pathogenesis and identify host immune pathways that mediate this attenuation. In addition, we describe novel treatment ave-
nues that exploit this pathway and could potentially be used against a diverse range of viral pathogens that utilize 2=-O-MTase
activity to subvert the immune system.
IMPORTANCE
Preventing recognition by the host immune response represents a critical aspect necessary for successful viral infection. Several
viruses, including SARS-CoV, utilize virally encoded 2=-O-MTases to camouflage and obscure their viral RNA from host cell
sensing machinery, thus preventing recognition and activation of cell intrinsic defense pathways. For SARS-CoV, the absence of
this 2=-O-MTase activity results in significant attenuation characterized by decreased viral replication, reduced weight loss, and
limited breathing dysfunction in mice. The results indicate that bothMDA5, a recognition molecule, and the IFIT family play an
important role in mediating this attenuation with restored virulence observed in their absence. Understanding this virus-host
interaction provided an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues for treat-
ment and prevention of emerging CoVs and other RNA virus infections.
Coronaviruses (CoVs) are large enveloped RNA viruses thatprimarily infect mammals and birds causing a range of eco-
nomically significant respiratory and enteric diseases (1). Human
CoVs cause medically relevant respiratory tract infections, and
most originated as zoonosis from bats (2). In 2003-2004, severe
acute respiratory syndrome CoV (SARS-CoV) emerged from
CoVs circulating between bats, civets, and raccoon dogs in open
markets causing severe acute respiratory disease with mortality
rates exceeding 50% in aged populations (3, 4). Although numer-
ous insights intoCoVpathogenesis have been developed, the virus
host-interactions that regulate disease severity remain poorly un-
derstood. In addition, the presence of CoV precursors in animal
reservoirs highlights the possibility of future emergent epidemic
strains as demonstrated by the recent emergence of Middle East
respiratory syndromeCoV in 2012 (5–10). Together, these factors
illustrate the need to understand the molecular mechanisms that
regulate and permit emerging virus infection, cross-species trans-
mission, and pathogenesis.
One area of interest involves transcription and translation of
viral mRNA during infection. Eukaryotic host mRNAs possess a
5=-terminal cap essential for efficient export, translation, and sta-
bility. Naturally, viral pathogens have coevolved mechanisms to
replicate this cap structure, thus permitting the use of the host cell
translational machinery and efficient replication (11–15). Ap-
proaches vary from utilization of the host capping machinery to
cap-snatching from host RNA (16). For many cytoplasmic RNA
viruses, significant genetic capital has been invested in viral pro-
teins that facilitate proper capping of viral mRNA. For CoVs, sev-
eral highly conserved nonstructural proteins (NSPs) have been
implicated in viral RNA capping activity, including NSP13
(RTPase) (17, 18), NSP14 (N7-methyltransferase [N7-MTase])
(19), and the NSP10/NSP16 2=-O-methyltransferase (2=-O-
MTase) complex (20–25). Although N7 methylation has been
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shown to be important in a variety of mRNA processing aspect,
the role of 2=-O methylation had been unclear (12). Recent re-
ports, however, detailed a role for 2=-O methylation in distin-
guishing self from nonself RNA within the host (12, 26). There-
fore, by encoding an active 2=-O-MTase in combination with
other capping features, viruses can subvert host recognition of
their mRNA and fail to induce a strong cell intrinsic immune
response.
The host response to infection begins with recognition of viral
intermediates by sensor molecules that induce type I interferon
(IFN); IFN signaling then regulates infection through production
of several hundred interferon-stimulated genes (ISGs) that initi-
ate an antiviral state and limit virus replication (27–29). The dis-
covery of 2=-O methylation in distinguishing between self and
non-self RNA accelerated interest in ISGs that target the absence
of this motif. MDA5, a RIG-I like molecule, has been shown to
recognize unmethylated 2=-O RNA and stimulate type I IFN (12).
Similarly, the IFIT family proteins have also been shown to recog-
nize capped RNA without 2=-O methylation but instead may se-
quester target RNA, thus blocking translation (26). Each ISG is
strongly induced during infection, but viruses have evolvedmech-
anisms to circumvent this type of recognition (11, 12, 30). How-
ever, absent these strategies, viruses would likely be sensitive to the
effector activities that target unmethylated 2=-O RNA.
With this inmind, we generatedmutants in SARS-CoVNSP16
that ablated 2=-O-MTase activity by targeting and replacing criti-
cal residues within a conserved motif. While the resulting viruses
remained replication competent, NSP16mutants were attenuated
in IFN competent cells and had reduced pathogenesis in vivo. Ad-
ditional studies confirmed increased type I IFN sensitivity but
failed IFN augmentation or restoration in IFNAR/mice. How-
ever, deficiency in either MDA5 or IFIT family members resulted
in enhanced replication in vitro and restored virulence in vivo.
Finally, targeting the 2=-O-MTase pathway as a live attenuated
vaccine platform provided a rational approach for improved pre-
vention of SARS-CoV infection. Overall, the work highlights the
importance of 2=-O-MTase activity within the context of SARS-
CoV pathogenesis and indicates that both MDA5, a recognition
molecule, and the IFIT family play an important role inmediating
this attenuation with restored virulence observed in their absence.
In addition, the attenuation and restoration of SARS-CoVvia viral
and host mutation provides a precise definition of pathway ma-
nipulation and a possible target pathway for future therapeutic
treatments.
MATERIALS AND METHODS
Viruses, cells, in vitro infection, and plaque assays.Wild-type and mu-
tant SARS-CoVswere cultured onVero E6 cells, grown inDulbeccomod-
ified Eagle medium (DMEM; Gibco, CA), and 5% fetal clone serum (Hy-
Clone, South Logan, UT), along with antibiotic/antimycotic (Gibco,
Carlsbad, CA). Growth curves in Vero, Calu-3 2B4, and human airway
epithelial (HAE) cells were determined as previously described (9, 31).
Briefly, cells were washed with phosphate-buffered saline (PBS) and in-
oculated with virus or mock diluted in PBS for 40 min at 37°C. After
inoculation, the cells were washed three times, and fresh medium was
added to signify time zero. Samples were harvested at described time
point. For IFN pretreatments, 100 U of recombinant human IFN- (PBL
Laboratories)/ml was added to Calu3 cells 16 h prior to inoculation and
infected as described above. All virus cultivation was performed in a BSL3
laboratory with redundant fans in biosafety cabinets as described previ-
ously by our group (32, 33). All personnel wore powdered air purifying
respirators (3M Breathe Easy) with Tyvek suits, aprons, and booties and
were double gloved.
Construction of NSP16 mutant viruses. Both wild-type and mutant
viruses were derived from either SARS-CoV Urbani or corresponding
mouse-adapted (MA15, referred to here as wild type [WT]) infectious
clone as previously described (33, 34). For NSP16 mutant construction,
the SARS E fragment (residues 18934 to 24057 of the SARS Urbani ge-
nome) cloned within the pSMART vector (Lucigen) was used for alanine
scanning mutagenesis of conserved residues in nsp16. For the K46A mu-
tation, two PCR products were generated by using the primers SARS 35
(5=-TGTTGCATTTGAGCTTTGGGC-3=; residues 19707 to 19727) and
NSP16A (5=-TGAGTATACGCTGCGACATTCATCATTATTCC-3=;
residues 20704 to 20734) or the primers NSP16A (5=-GTCGCAGCGT
ATACTCAACTGTGTCAATAC-3=; residues 20716 to 20748) and
10AgeI (5=-CATCAAGCGAAAAGGCATCAG-3=; residues 21986 to
22006). The two products were gel purified and joined in an overlapping
PCR using primers SARS 36 (5=-TGGAGATTTCAGTCATGGAC-3=; res-
idues 20261 to 20280) and 9AgeI (5=-GTTGAGTGTAATTAGGAGCT
TG-3=; residues 21568 to 21589). The resultant product was digested with
BbsI and ligated into the SARS E plasmid. For the K170A mutation, frag-
ments were amplified with the primers SARS 35 and NSP16B (5=-GCT
CTGTTATCGCTACAGCTATAGAACCACCCAG-3=; residues 21076 to
21109) or with primers NSP16B (5=-AGCTGTAGCGATAACAGAGCA
TTCTTGGAATGC-3=; residues 21090 to 21121) and 10AgeI. These two
products were subsequently joined in an overlap PCR using the SARS 36
and 9AgeI primers. The resulting product was digested with BbsI and
inserted into the SARS E plasmid. For the D130A change, a product was
generated by PCR using primers NSP16C (5=-AAATGGGACCTTATT
ATTAGCGCGATGTATGACC-3=; residues 20956 to 20989) and
10AgeI. This amplicon was digested with PpuMI and AgeI and then
ligated into the SARS E plasmid, which had been similarly digested.
Thereafter, plasmids containing wild-type and mutant SARS-CoV ge-
nome fragments were amplified, excised, ligated, and purified. In vitro
transcription reactions were then performed to synthesize full-length
genomic RNA, which was transfected into Vero E6 cells. The media from
transfected cells were harvested and served as seed stocks for subsequent
experiments. Viral mutants were confirmed by sequence analysis prior to
use. Synthetic construction of mutants of NSP16 were approved by the
University of North Carolina Institutional Biosafety Committee.
RNA isolation, microarray processing, and identification of differ-
ential expression. RNA isolation andmicroarray processing fromCalu-3
cells was carried out as previously described (35). Differential expression
(DE) for IFNb1, IFIT1, IFIT2, and MDA5 was determined by comparing
virus-infected replicates to time-matchedmock replicates. The criteria for
DE were an absolute log2-fold change of1.5 and a false discovery rate-
adjusted P value of0.05 for a given time point.
Construction of stable-shRNA cell lines. Plasmids containing both
green fluorescent protein (GFP) and shRNA targeting IFIT1 or IFIT2were
a gift from Michael Diamond (Washington University). Plasmids were
amplified and transfected into Vero E6 cells by using Lipofectamine 2000
(Invitrogen) according to the kit protocols. After transfection, cells un-
derwent puromycin selection for 1 week and were analyzed for GFP ex-
pression, with90% of the cells appearing GFP positive. Cells were then
IFN treated and infected as described above.
Ethics statement. The present study was carried out in accordance
with the recommendations for care and use of animals by the Office of
Laboratory Animal Welfare, National Institutes of Health. The Institu-
tional Animal Care and Use Committee (IACUC) of The University of
North Carolina at Chapel Hill (UNC; permit A-3410-01) approved the
animal study protocol (IACUC 13-033) followed here.
Mouse infections and vaccinations. Ten-week-old BALB/c or
C57BL/6 mice were anesthetized with ketamine and xylazine (in accor-
dance with IACUC/UNC guidelines) and intranasally inoculated with a
50-l volume containing 105 PFU of SARS-CoVWT virus or SARS-CoV
dNSP16 virus or PBS mock infected as indicated in the figure legends.
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Infected animals were monitored for weight loss, morbidity, clinical signs
of disease, and lung titers were determined as described previously (36).
For vaccination experiments, 10-week-old BALB/c mice were infected
with 102 PFU of dNSP16 as described above,monitored for clinical symp-
toms for 7 days, and then challenged at 4 weeks postvaccination with 105
PFU of SARS-CoV MA15. Female BALB/c mice were purchased from
Harlan Labs; IFIT1/ and MDA5/ mice, previously described (26,
37), were obtained from Michael Diamond and Marco Colonna (Wash-
ington University, St. Louis, MO), bred in-house, and both male and
female mice were used for studies; male and female control C57BL/6J and
IFNAR/ mice were obtained from The Jackson Laboratory (Bar Har-
bor, ME) and an equivalent male/female ratio used for the IFIT1/,
MDA5/ and C57BL/6J infection groups. Animal housing, care, and
experimental protocols were in accordance with UNC IACUC guidelines.
Whole-body plethysmography. Unrestrained whole-body plethys-
mography was completed using individual plethysmography chambers
(Buxco Research Systems, Wilmington, NC) as previously described (38,
39). Briefly, infected or mock treated animals are introduced to a pleth-
ysmography chamber located within a biosafety cabinet in a BSL3 labora-
tory and allowed to acclimate for 30 min. After acclimation, breathing
parameters were measured for a 5-min period. Animals were then re-
turned to their cages and monitored as described above. Animals were
introduced into the chamber once per day, with their first introduction
into the plethysmography chamber immediately prior to infection, and
thereafter at indicated time points postinfection. Animals were randomly
assigned to a given chamber each day. Generated data were analyzed via
Finepoint software (Buxco Research Systems). Whole-body plethysmog-
raphy protocols were carried out in accordance with UNC IACUC guide-
lines.
Histological analysis of infected mice. Lung tissues for histological
analysis were prepared as described previously (40). Briefly, lung tissue
was fixed in 10% formalin (Fisher) for at least 7 days, tissues were embed-
ded in paraffin, and 5-m sections were prepared by the UNC histopa-
thology core facility. To determine the extent of inflammation, sections
were stained with hematoxylin and eosin (H&E) and scored in a blinded
manner. Scoring evaluated pathological changes in the airways (apopto-
sis, denuded airway epithelial cells, debris, inflammation [scored from 0
to 3]), vasculature (perivascular cuffing [scored from 0 to 3]), and the
parenchyma (hyaline membranes, inflammation, and edema [scored
from 0 to 3]). Images were captured using an Olympus BX41 microscope
with an Olympus DP71 camera.
Meta-analysis of WT SARS-CoV infection. In vitro and in vivo RNA
expression and proteomics data were derived from previous studies with
SARS-CoV (31, 40). The raw microarray data are accessible through the
NCBI Gene Expression Omnibus (GEO) (41) through GEO series acces-
sion numbers GSE33267 and GSE33266. Raw proteomics data corre-
sponding to peptide identifications used to populate the AMT tag data-
base are available at the PRoteomics IDEntification (PRIDE) database
(http://www.ebi.ac.uk/pride/) under the project name “A Systems Biol-
ogyApproach to EmergingRespiratoryViral Diseases” in the PRIDEPub-
lic Projects folder and corresponding to PRIDE accession numbers 19855
to 19860 and 19877 to 19890. The raw quantitative proteomics data can be
accessed at the Pacific Northwest National Laboratory’s Biological Mass
Spectrometry Data and Software Distribution Center (http://omics.pnl
.gov/) in the systems virology contract data folder within the browse avail-
able data folder. All data sets and associated metadata have been submit-
ted to Virus Pathogen Resource (http://www.viprbrc.org). Additional
details from the present study and similar studies can be accessed through
the Systems Virology website (http://www.systemsvirology.org).
RESULTS
CoV NSP16 are members of the S-SAM-dependent 2=-O-MTase
family (20); although they share little sequence identity, each
member maintains a KDKE catalytic tetrad required for activity
(Fig. 1A). Mutation at any one of these residues ablates 2=-O-
MTase function (21). In addition, NSP16, unlike other 2=-O-
MTases, also requires a stimulatory subunit, NSP10 (20). Target-
ing either its catalytic subunit or the interaction with NSP10
provides a means to ablate 2=-O methylation of CoV mRNA and
evaluate NSP16’s impact on pathogenesis (Fig. 1A). In the present
study, we focused on the catalytic tetrad. Using the SARS-CoV
Urbani infectious clone (33), we generated three mutant viruses
with individual alanine substitution within the NSP16 tetrad
(K46A, K170A, and D130A [Fig. 1A, inset]), shown to ablate 2=-
O-MTase function in vitro biochemical assays for coronaviruses
(25). Each virus was viable and grew to robust titers in Vero cells
following a low-multiplicity infection (Fig. 1B).However, all three
mutants were attenuated after infection of IFN competent Calu3
respiratory cells; endpoint titers revealed an approximately 10- to
500-fold reduction in log endpoint titers 48 h postinfection (hpi),
depending on the mutant (Fig. 1C). With future in vivo experi-
ments in mind, we constructed a mouse-adapted mutant NSP16
virus based on the D130A mutation. This mutation had main-
tained the most robust replication in Calu3 cells, required no ad-
ditional passages to generate robust stock titers, and corresponded
to a previously generated mutant in related mouse hepatitis virus
(26). The resulting mouse-adapted NSP16 mutant virus
(dNSP16) alsomaintained equivalent replication in Vero cells rel-
ative to wild-type mouse-adapted SARS-CoV (MA15; referred to
here asWT [data not shown]), and bothwere used for the remain-
der of the experiments.
NSP16 mutant viruses are attenuated at late time points in
respiratory cells and in vivo. Using the mouse-adapted D130A
mutant (dNSP16), we evaluated its ability to replicate in immu-
nocompetent respiratory cells without its 2=-O-MTase activity. In
Calu3 cells, dNSP16 viruses maintains similar replication kinetics
toWTSARS-CoVover the first 24 hpi; however, at late timepoints
(48 and 72 hpi), an 10-fold attenuation was noted in dNSP16
infection, which is consistent with the Urbani mutant NSP16 vi-
ruses (Fig. 2A). Similarly, primary human airway epithelial (HAE)
cultures alsomaintained a 5- to 10-fold reduction in titer at a later
time point, indicating attenuation in cells typically targeted by
SARS-CoV in humans (Fig. 2B). Together, the data indicated that
the absence of 2=-O-MTase activity has an impact during a low-
multiplicity infection of immunocompetent respiratory cells.
Initial in vivo studies in 10-week-old BALB/cmice also revealed
marked attenuation of dNSP16 compared to WT SARS-CoV. At
early time points, dNSP16-infected mice maintained equivalent
levels of weight loss to WT-infected animals (Fig. 2C). However,
as the infection progressed, dNSP16-infected mice begin to re-
cover weight and have increased survival compared to WT-in-
fected mice (Fig. 2C and data not shown). Similarly, although
virus titers in the lung remain equivalent at day 2 postinfection, a
nearly 1,000-fold decrease in dNSP16 virus titer is observed at 4
days postinfection (dpi) (Fig. 2D). Examination of lung function
also revealed a significant attenuation in dNSP16-infected
mice. Both measured airway resistance (penH) and expiratory
flow rates (EF50) showed only minimal signs of disease after
infection with the dNSP16 mutant (Fig. 2E and F). In contrast,
after WT infection airway resistance and expiratory flow diffi-
culties peaked at days 2 and 4, respectively, a finding consistent
with previous studies (V. D. Menachery et al., unpublished
data). Together, the data indicated a robust attenuation of
SARS-CoV mutant lacking 2=-O-MTase activity in a variety of
pathogenic outcomes.
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dNSP16 mutant viruses are sensitive to type I IFN but not
completely restored by its absence in vivo. Attenuation at late
time points after both low-multiplicity infection and in vivo is
possibly indicative of sensitivity to bystander/feedback IFN signal-
ing. Coupled with minimal attenuation in Vero cells, which lack
IFN production (42), the data suggested that dNSP16 mutants
were sensitive to the type I IFN response. To test this idea, Vero
cells were pretreated with 100 U of IFN-/ml 16 h prior to infec-
tion with either dNSP16 or WT SARS-CoV. After a high-multi-
plicity infection, IFN treatment had little to no impact on WT
SARS-CoV replication; in contrast, IFN pretreatment resulted in
the substantial attenuation of dNSP16 with a nearly 10,000-fold
reduction in virus titer 24 hpi compared to untreated cells (Fig.
3A). Together, the results confirm that IFN resistance demon-
strated byWT SARS-CoV requires the continued maintenance of
the 2=-O-MTase activity of NSP16.
Having demonstrated increased sensitivity of dNSP16 to type I
IFN, we next sought to determine whether an increased IFN re-
sponse played a significant role in mutant virus attenuation. After
infection with either WT SARS-CoV or dNSP16, Calu3 cells
showed no augmentation or changes in underlying kinetics of the
type I IFN response (Fig. 3B). Examining the expression of IFNB1
FIG 1 Construction of SARS-CoVNSP16mutant viruses. (A) SARS-CoVNSP16 protein (black) bound to NSP10 (orange) based on published crystal structure
(21). The individual residues of the conservedKDKEmotif required forMTase function are highlighted in complex, and the insets (on the right side) demonstrate
wild-type and constructed NSP16 mutants with alanine substitution at circled residues. (B and C) Endpoint virus titers of wild-type icSARS-CoV and icSARS
NSP16 mutants in Vero cells (multiplicity of infection [MOI]	 0.01) (B) and Calu3 airway epithelial cells (MOI	 0.01) (C).
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indicated that bothWT and dNSP16 infections had delayed (12
hpi), but nevertheless substantial induction of type I IFN tran-
scripts at late times. Similarly, C57BL/6 mice infected withWT or
mutant saw no change in IFNB1, as measured bymicroarray anal-
ysis (Fig. 3C). Similar results were observed for both IFNA4 and
IFNL1 both in vitro and in vivo (data not shown). In addition,
infection of mice lacking type I IFN receptor (IFNAR/) also
suggested that IFN played an important, but limited role
in dNSP16 attenuation. After infection, dNSP16-infected
IFNAR/mice maintained slightly augmented virus titers com-
pared toWT SARS-CoV at 2 dpi. By day 4, dNSP16 demonstrated
a smaller, but significant 10-fold reduction in lung titer compared
toWT (Fig. 3D). Relative to the deficit observed in wild-typemice
(Fig. 2D), this represented a nearly 100-fold augmentation of viral
replication. However, partial restoration of viral replication in
IFNAR/ mice failed to impact pathogenesis since the weight
loss data indicated continued attenuation of dNSP16 (Fig. 3E).
Together, the data showed that type I IFNplays a significant role in
replication deficits of dNSP16, but additional factors contribute to
attenuation independent of downstream type I IFN signaling.
IFIT andMDA5 deficiency restores SARS-CoV dNSP16 mu-
tant. Having demonstrated that type I IFN deficiency alone was
insufficient to restore virulence to dNSP16mutant SARS-CoV,we
next sought to determine whether IFN augmented, but indepen-
dent antiviral genes play a prominent role. Recentworks had iden-
tified 2=-O methylation as a critical distinction between self and
nonself RNA. Therefore, we chose to focus on host antiviral pro-
teins that had previously been shown to target RNA species lack-
ing 2=-O methylation and are IFN independent: MDA5 and the
IFIT family of proteins (12, 26). Notably, both IFIT1 and MDA5
had been previously been shown by our group to be induced even
in the absence of type I IFN receptor during SARS-CoV infection
(43). Using a comprehensive systems biology approach with RNA
(20,000 transcripts) andproteomic data (2,000 proteins) (31),
MDA5, IFIT1, and IFIT2 expressionwere examined followingWT
SARS-CoV infection of Calu3 cells (Fig. 4A to C). The results
FIG 2 dNSP16mutant viruses attenuation in vitro and in vivo. (A and B) Virus titers after infection of Calu3 cells (A) or human airway epithelial (HAE) cells (B)
with SARS-CoVWTor dNSP16 at anMOI of 0.01. Time zero represents input titers. (C to F)Weight loss (n 5 forWT and dNSP16 groups) (C), lung virus titer
(n	 3 per group) (D), airway resistance (E), and expiratory flow (F) after infection of female BALB/c mice with 105 PFU of SARS-CoVWT or dNSP16. P values
based on the Student t test are marked (*, P 0.05; ***, P 0.001).
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indicated that both MDA5 and IFIT family members were in-
duced at the RNA and protein levels. In addition, when the pro-
teomic values are overlaid with replication during low-multiplic-
ity infection (Fig. 2A), the kinetics of MDA5 and IFIT protein
production corresponded with the kinetics of dNSP16 attenua-
tion. Similarly, in vivo proteomics data show that both RNA in-
duction and protein production of MDA5, IFIT1, and IFIT2 peak
at 4 dpi, which also corresponds to in vivo attenuation of dNSP16
(Fig. 4D to F) (40). However, in vitro studies directly comparing
WT and dNSP16 revealed neither earlier induction nor aug-
mented expression of IFIT1, IFIT2, or MDA5 after the mutant
infection (Fig. 5A to C). Similarly, C57BL/6 mice infected with
either WT or dNSP16 showed no distinction in the magnitude or
kinetics of expression (Fig. 5D to F). These results suggested that
the deficit in dNSP16 derives from the IFIT effector function
rather than augmented sensing and signaling provided by MDA5
(44, 45). To confirm the effector role of IFIT1 and IFIT2, we ob-
served dNSP16 replication in their absence. GFP-expressing
shRNA constructs were used to develop stable IFIT1, IFIT2, and
MDA5 knockdown (KD) Vero cell lines under puromycin selec-
tion. After IFN pretreatment, both IFIT1 and IFIT2 KD cells in-
fected with WT SARS-CoV exhibited a modest increase in viral
replication at 24 hpi (Fig. 5G); by 48 hpi, WT virus titers are
equivalent in control and KD cell lines, likely due to NSP16 activ-
ity. In contrast, dNSP16 infection resulted in a substantial increase
in viral replication in both IFIT1 and IFIT2 KD cell lines pre-
treated with IFN (Fig. 5H). In addition, MDA5 KD cells demon-
strated no measurable change inWT or dNSP16 replication (data
not shown). Together, these results suggested that IFN-dependent
attenuation of dNSP16 is strongly, but not completely dependent
on the individual effector activities of IFIT1 and IFIT2.
Having established an effector role for the IFIT family in
FIG 3 dNSP16 is more sensitive to IFN but is not restored by type I IFN deficiency. (A) Mock-treated (solid lines) or IFN- pretreated (dotted lines) Vero cells
infected with either SARS-CoVWT (black) or dNSP16 (red) at an MOI of 5. (B) Percentage reduction in log virus titer derived from panel A for WT (black) or
dNSP16 (red). (C and D) RNA expression of IFNb1 from Calu3 cells (C) or C57BL/6 (D) mice after infection with WT or dNSP16 SARS-CoV. (E and F) Viral
lung titers (n 3 per group) (E) and weight loss (n 6 per group) (F) after infection of female, 10-week-old IFNAR/mice with SARS-CoV WT (black) or
dNSP16 (red). P values based on the Student t test are marked (*, P 0.05; ***, P 0.001).
Menachery et al.
4256 jvi.asm.org Journal of Virology
dNSP16 attenuation in vitro, we next sought to examine the role of
IFIT1, as well as the sensor molecule MDA5, in vivo. Male and
female 10-week-oldWT,MDA5/, and IFIT1/C57BL/6mice
were infected with either dNSP16 or WT and monitored over a
7-day time course. C57BL/6 mice maintained attenuation of
dNSP16 relative toWT in terms ofweight loss and viral replication
confirming BALB/c results (Fig. 6A). In contrast, both MDA5/
and IFIT1/mice resulted in restored virulence for dNSP16. In
the absence ofMDA5 or IFIT1, dNSP16 caused similar weight loss
as WT in both mouse lines (Fig. 6B and C). Similarly, the absence
of either of these proteins resulted in D4 virus titers equal to or
greater than WT titers in WT mice (Fig. 6D). Although the ab-
sence of MDA5 and IFIT1 enhanced WT replication at day 4, no
concurrent change in weight loss was observed. This result sug-
gested that MDA5 and IFIT1 still impacted WT SARS-CoV repli-
cation but did not alter pathogenesis. Notably, the absence of ei-
ther IFIT1 or MDA5 restored the ability of dNSP16 to cause
breathing difficulties. Changes in airway resistance (penH) and
expiratory flow rate (EF50) after dNSP16 infection overlapped
changes observed duringWT infection (Fig. 6E to G). In addition,
lung sections revealed that attenuation of dNSP16 inC57BL/6was
reversed in bothMDA5/ and IFIT1/mice (Fig. 7). Although
day 2 and day 4 showed only minor changes (data not shown),
examination of day 7 histology revealed reduced disease in
dNSP16-infected B6 mice relative to WT infection in terms of
broad lung disease, edema, and vascular cuffing (Fig. 7A and B) In
contrast, both MDA5/ and IFIT1/mice had broad similari-
ties in lung damage between WT and dNSP16 (Fig. 7C to F). In
addition, while airway disease remained similar in all groups (data
not shown), the dNSP16 attenuation in edema and vasculature
disease was absent in IFIT1/ and MDA5/, as measured by
histology scoring (Fig. 7G to H). Together, the infection data il-
lustrated that the absence of SARS-CoV 2=-O-MTase was comple-
mented by the absence of either MDA5 or IFIT1, thus restoring
pathogenesis to dNSP16 in vivo.
Targeting 2=-O-MTase pathways for vaccination. Effective
treatments for SARS-CoV and other CoV infection do not cur-
rently exist (18, 57). Therefore, studying and targeting 2=-Ometh-
ylationmay provide novel strategies for developing effective treat-
ments to SARS-CoV and potentially global methods to rationally
design treatments for other RNA viruses. In vivo attenuation
raised the possibility of utilizing 2=-O-MTase mutants as a live-
attenuated vaccine backbone. This approach permits robust viral
replication during early times, but accelerated viral clearance
FIG 4 Kinetic expression ofMDA5 and IFIT proteins correspond to dNSP16 attenuation. (A toC)RNA (solid line) and protein (dashed line) expression of IFIT1
(A), IFIT2 (B), andMDA5 (C) in Calu3 cells after infectionwithWT icSARS-CoV. (D to F) RNA (solid) and protein (dashed) expression of IFIT1 (D), IFIT2 (E),
and MDA5 (F) after infection of C57BL/6 mice.
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FIG 5 ISG expression kinetics and effector function after in vitro infection with dNSP16. (A to C) In vitro RNA expression of IFIT1 (A), IFIT2 (B), and MDA5
(C) after infection at an MOI of 5 of Calu3 cells with WT SARS-CoV (black) or dNSP16 (red), as measured by microarray. (D to F) In vivo RNA expression of
IFIT1 (D), IFIT2 (E), and MDA5 (F) after infection of C57BL/6 mice with WT SARS-CoV (black) or dNSP16 (red). (G to H) Vero cells expressing shRNA
targeting IFIT1 (blue), IFIT2 (purple), or no shRNA (black) were pretreated with IFN- and infected with WT SARS-CoV (G) or dNSP16 (H). P values based
on Student t test and are marked as indicated (*, P 0.05; ***, P 0.001).
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and immune priming at late times postinfection. To evaluate
dNSP16 as a possible vaccine, 10-week-old BALB/c mice were
vaccinated with 102 PFU of dNSP16 or PBS mock infected.
Animals were monitored for 7 days and subsequently chal-
lenged with a lethal dose (105) of SARS-CoV WT at 4 weeks
postvaccination. The results demonstrated that dNSP16-in-
fected mice suffered minimal weight loss during initial vacci-
nation (data not shown). Postchallenge with WT, vaccinated
mice lost 5% of body weight and were protected from lethal
challenge (Fig. 8A and B). In contrast, mock-vaccinated mice
showed significant weight loss, and all mice died by day 4. In
addition, serum from vaccinated mice proved to be effective in
neutralizing WT control virus with plaque reduction neutral-
ization test 50 (PRNT50) titers exceeding 1/1,600 (Fig. 8C).
FIG 6 Pathogenesis after infection of MDA5/ or IFIT1/ mice with dNSP16. (A to H) Male and female C57BL/6 (black, n  13 per group), MDA5/
(green, n 13 per group), and IFIT1/ (blue, n 8 per group) mice were infected with SARS-CoVWT (solid lines) or dNSP16 (dashed line) and monitored
for weight loss (A to C), virus titer in the lung (D), expiratory flow (E and F), and airway resistance (G and H). For panels E to H, data from mock-infected
IFIT1/ (twomice) andMDA5/ (onemouse) animals were combined to provide a relative baseline for respiratory function. P values based on Student t test
and are marked as indicated (*, P 0.05; **, P 0.01; ***, P 0.001).
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FIG 7 Histological analysis of C57BL/6, IFIT1/, and MDA5/mice after infection with WT-SARS-CoV and dNSP16. (A to F) Representative images show
broad lung cross-sections (first column, 10
), alveolar edema (second column, 40
), and vascular cuffing (third column, 40
) afterWT-SARS-CoV (A, C, and
E) or dNSP16 (B, D, and F) infection of C57BL/6 (A and B), IFIT1/ (C andD), andMDA5/ (E and F)mice. (G andH) Blinded histology scoring of alveolar
exudates (G) and vasculature disease (edema and perivascular cuffing) (H) afterWT (solid) or dNSP16 (hatched) infection of C57BL/6 (black), IFIT1/ (blue),
and MDA5/ (green) mice 7 days postinfection. P values based on Student t test and are marked as indicated (*, P 0.05).
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Together, the data demonstrated that targeting viral 2=-O-
MTases as a valid strategy for rapid, rational vaccine design.
DISCUSSION
The data in this study illustrate both the importance of 2=-O-
MTase activity to SARS-CoV pathogenesis and the immune path-
ways that target this activity to mediate antiviral defense. While
NSP16 activity has only a minimal impact on the underlying viral
life cycle of SARS-CoV, its absence resulted in significant attenu-
ation under immune selective pressure. In vitro, the lack of 2=-O-
MTase activity resulted in a modest, but significant reduction in
virus titers at late time points in both an immunocompetent re-
spiratory cell line and primary human airway cultures. Similarly,
in vivo attenuation was observed in regard to viral replication,
weight loss, and breathing functionality following dNSP16 infec-
tion. In addition, the absence of NSP16 activity rendered the mu-
tant virus exquisitely sensitive to type I IFN pretreatment. How-
ever, despite the enhanced sensitivity, knocking out type I IFN
signaling was not sufficient to fully restore virulence to the NSP16
mutant virus in vivo. Further analysis revealedMDA5 and the IFIT
family members, both of which target unmethylated 2=-O capped
RNA, as critical inmediating dNSP16 attenuation. The absence of
either MDA5 or IFIT1 in vivo resulted in augmented replication,
restoredweight loss, and reduced breathing functionality replicat-
ing phenotypes seen in SARS-CoV WT-infected controls. To-
gether, the data illustrate the attenuation and restoration of SARS-
CoV mutant lacking 2=-O-MTase activity and have possible
implications for future therapeutic treatments.
The attenuation of SARS-CoV 2=-O-MTase mutants was con-
sistent with reports in other RNA viruses. Both flaviviruses and
murine coronaviruses have been generated previously, targeting
substitutions with the same KDKE motif utilized in these studies
(12, 26, 46, 47). Although these mutant viruses have been shown
to be viable without 2=-O-MTase activity, they maintain IFN
based attenuation in vitro and in vivo. Similarly, SARS-CoV
dNSP16 had normal replication kinetics and increased sensitivity
to type I IFN treatment relative to WT. However, unlike 2=-O-
MTase mutants in other coronaviruses (12), dNSP16 failed to
induce a more robust type I IFN response. Similarly, while the
absence of type I IFN receptor augmented viral replication in vivo,
it failed to restore virulence to dNSP16, in contrast to previous
findings withWest Nile virus (26). Together, the results indicated
that despite increased IFN sensitivity, dNSP16 maintained the
ability to antagonize the type I IFN response equivalently to WT
SARS-CoV. In addition, the data indicate that host pathways in-
dependent of type I IFN play a substantial role in limiting dNSP16
pathogenesis in vivo.
Shifting focus, we next examined MDA5 and IFIT proteins
which had previously been shown to play important roles in me-
diating attenuation of 2=-O-MTase mutants. Both MDA5 and
IFIT familymembers are IFN responsive genes (48) but have been
shown to be induced after SARS-CoV infection independent of
type I IFN receptor (43). Based on host transcription and protein
kinetics followingWT SARS infection, bothMDA5 and IFIT pro-
duction corresponded with attenuation of dNSP16 in vitro and in
vivo. Similarly, SARS-CoV dNSP16 virus infection of either
IFIT1/ or MDA5/ mice resulted in restored virulence in
terms of viral replication and weight loss relative toWT. Notably,
the results also showed restored pathogenesis in terms of breath-
ing dysfunction in mice and histology scoring. While SARS-CoV
dNSP16 infection resulted in minimal breathing changes in wild-
type mice, both airway resistance and lung flow rate were reduced
after dNSP16 infection with levels equivalent to WT in IFIT1/
andMDA5/mice. These results contrastwith findings observed
withWestNile virus, dengue virus, andmouse hepatitis virus that,
despite augmented viral replication and tissue distribution in
IFIT1/ andMDA5/mice, failed to fully restore virulence and
pathogenesis to the 2=-O-MTase mutants (12, 26, 46). This con-
trast within 2=-O-MTasemutants in the same and other viral fam-
ilies suggests that tissue and pathogen specificity may play a sig-
nificant role in differences in mutant restoration. A previous
report has detailed differing requirements for IFIT1 and IFIT2 in
FIG 8 Vaccination with dNSP16 protects from lethal challenge. (A and B)
Weight loss (A) and lethality (B) after infection of 10-week-old female BALB/c
mice vaccinated with 100 PFU of dNSP16 or PBS (n 	 6), monitored for 28
days, and then challenged with SARS-CoVWT at 105 PFU. (C) Neutralization
titer for WT-SARS-CoV from serum of dNSP16-vaccinated mice or mock-
vaccinated mice 28 days postinfection. P values are based on the Student t test
and are marked as indicated (*, P 0.05; **, P 0.01; ***, P 0.001).
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the brain versus peripheral tissues following viral challenge (49).
In addition, cell-specific and tissue-specific immune responses
vary greatly between the target cells of mouse hepatitis virus (liver
cells), flaviviruses (immune cells), and SARS-CoV (lung epithe-
lia), thus altering the necessity and requirements for specific ISGs.
Within the lung, it appears that both MDA5 and IFIT family
members play critical roles in mediating attenuation of SARS-
CoV2=-O-MTasemutant, and these genes are augmented, but not
dependent on type I IFN.
Understanding the attenuation and host-mediated restoration
of dNSP16 provides an opportunity to design novel therapeutics
that target this pathways for treatment of CoV and other RNA
virus infections. Effective treatments and vaccines for SARS-CoV
and other CoV infection do not currently exist (18, 57). Both
subunit and adjuvanted-killed vaccines have been explored but
have been plagued by vaccine failure and/or induced immune
pathology, especially in aged animal models (36, 50–52). Two live
attenuated vaccine platforms that employ amutation in ExoNor a
deletion in the E protein have been shown to be effective in both
young and oldmice (52–54).However, recentwork suggested that
a sufficient level of viral replication is required to initiate robust
immunity (52), and both the ExoN and E mutants have signifi-
cant attenuation of viral replication, even at early time points fol-
lowing infection. In contrast, in vivo attenuation of dNSP16 sug-
gested that vaccination with this mutant could maintain robust
replication at early time points but would induce rapid, immune-
based clearance at late time points. Our results indicated that vac-
cination of young animals with a low dose of dNSP16 resulted in
complete protection fromhomologousWT SARS-CoV challenge.
In young animals, dNSP16-induced neutralization titers exceeded
those of most vaccine platforms tested to date, recognizing that
direct comparisons are very difficult because of variations in pro-
tocols, vaccine doses, age, challenge doses, and other study design
conditions (36, 50, 52, 54). While further study is required, espe-
cially inmore vulnerable aged populations, the present study pro-
vides a proof of principle in utilizing 2=-O-MTase mutants as a
successful vaccine platform for CoVs and is consistent with a sim-
ilar approach using the 2=-O-MTase mutant of dengue virus as a
successful live-attenuated vaccine (46).
In addition to a vaccine platform, targeting the 2=-O-MTase
pathway for drug treatment provides a novel means to treat CoV
infection. One approach would directly target the catalytic KDKE
domain of the viral MTase blocking its target binding. This ap-
proach would result in IFN-based attenuation and possibly prove
effective against any virus that uses a virally encoded 2=-O-MTase.
A second approach disrupts CoV infection by directly preventing
interaction with NSP10, a required component for CoV NSP16
activity (20). For both approaches, target drugs and small peptide
inhibitors exist (55, 56), but effective treatment must also over-
come type I IFN blockade induced by the virus, thus permitting
the production of immune effectors that mediate attenuation.
Therefore, drugs targeting this pathway may prove most effective
in combination with IFN stimulatory agents.
Overall, we demonstrate here that SARS-CoV viruses that lack
2=-O-MTase activity are viable but attenuated both in vitro and in
vivo. In addition, the results indicate that while attenuation is
immune mediated, it is only partially dependent on type I IFN.
Further examination confirmed that both MDA5 and IFIT fam-
ily members were necessary components required to mediate
dNSP16 attenuation. In the absence of either MDA5 or IFIT1,
dNSP16 SARS-CoV had fully restored replication and pathogen-
esis in vivo, successfully complementing the deficit in the 2=-O-
MTase activity. Together, these findings have significant implica-
tions for both the understanding and the treatment of SARS-CoV
and future emerging respiratory coronavirus infections, including
MERS-CoV infections.
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